Wave Life Sciences Ltd. (Nasdaq: WVE) said its RNA-editing drug for a rare genetic disease reduced a harmful liver protein by 71 percent while restoring a protective version, bolstering its case for a therapy that could treat both lung and liver damage.
"We have now seen consistent results across multiple cohorts that reaffirm WVE-006’s potential to protect the liver by reducing the toxic Z-AAT protein, while simultaneously enabling a dynamic response capable of protecting the lung," Christopher Wright, Chief Medical Officer at Wave Life Sciences, said in a statement. He added the approach avoids permanent genomic mutations associated with DNA editing.
The updated Phase 1b/2a data showed the 200 mg biweekly dose of WVE-006 achieved a 70.5% reduction in harmful Z-AAT protein and restored wild-type M-AAT to 64.4% of total AAT, a level consistent with low-risk individuals. A 400 mg monthly dose showed similar robust effects, with a 67.7% Z-AAT reduction and total AAT levels of 13.6 µM, supporting a convenient, infrequent dosing schedule.
The results position WVE-006 as a potential new standard of care for alpha-1 antitrypsin deficiency (AATD), a condition where the only approved therapy addresses only lung symptoms. With FDA feedback on a possible accelerated approval path expected in mid-2026, Wave’s progress could challenge other companies in the genetic medicine space like ZYME and AMLX.
Alpha-1 antitrypsin deficiency is caused by a mutation that leads to the production of dysfunctional Z-AAT protein, which accumulates in the liver and causes damage, while failing to produce enough protective M-AAT protein to shield the lungs. WVE-006, a GalNAc-conjugated RNA editing therapy, is designed to correct the underlying mutation at the RNA level, allowing the patient’s own body to produce functional M-AAT.
The RestorAATion-2 trial data demonstrated this dual action effectively. Beyond the multi-dose cohorts, single doses also showed dose-dependent reductions in Z-AAT and restoration of M-AAT. Notably, the study observed three instances where patients mounted a dynamic AAT response to infections, with one patient’s total AAT level surging to 20.6 µM, showing the restored protein can function as needed. The therapy has been well-tolerated, with all adverse events rated mild to moderate.
Wave Life Sciences is on track to receive feedback from the U.S. Food and Drug Administration on a potential accelerated approval pathway by mid-2026, a key catalyst for the program. The company plans to release data from a higher, 600 mg monthly dose cohort in the second half of 2026, which could further solidify the drug's profile.
Investors are watching closely, though the positive data did not prevent a 1.88% dip in WVE shares to $6.77 on the day of the announcement. The stock trades significantly below its 52-week high of $21.73. With a reported cash runway extending into the future after a Q1 update and a median analyst price target of $29.5, the clinical data may represent a valuation disconnect. The company's pipeline also includes programs for obesity and Duchenne muscular dystrophy, providing multiple avenues for growth.
This article is for informational purposes only and does not constitute investment advice.
